Updated Long-Term Follow-Up From the Phase 1b BOT+BAL Study at ESMO GI 2026 – Agenus
oncodaily - Agenus shared a post on LinkedIn: “At ESMOGI26, Agenus will share updated long-term follow-up from the Phase 1b study evaluating botensilimab plus balstilimab (BOT+BAL) in patients with MSS metastatic colorectal […]
AI Summary: Updated follow‑up data presented for botensilimab plus balstilimab reveal meaningful and durable activity in microsatellite‑stable metastatic colorectal cancer, with especially encouraging outcomes in patients lacking active liver metastases. The Agenus combination, showcased at a major gastrointestinal oncology meeting, renews interest in immune strategies for historically refractory MSS disease.
- Agenus releases Phase 1b three-year BOT+BAL survival data (2)
- Clinical and community reaction: experts weigh in on BOT+BAL (3)
- ESMO GI: BOT+BAL benefits in patients without active liver metastases (3)
- All Other Stories
Agenus releases Phase 1b three-year BOT+BAL survival data
Clinical and community reaction: experts weigh in on BOT+BAL
ESMO GI: BOT+BAL benefits in patients without active liver metastases
All Other Stories
Related Stories
EMERALD‑3 tests tremelimumab/durvalumab combos for embolisation‑eligible HCC / 7 days
Zanidatamab improves PFS over trastuzumab in HER2 GEA / 5 wks
MAGE‑A4/A8 TCR bispecific T‑cell engager shows activity in solid tumors / 5 wks
Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 6 wks
Common asthma drug may overcome immunotherapy resistance in cancers / 7 wks
Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 7 wks
Zoldonrasib shows durable responses in KRAS G12D lung cancer / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Biotech, Cancer Screening, Weight Loss, Telemedicine and look for the RSS link.
StackHealth Time Machine